Management of Inpatient Insomnia

First-Line Treatment Approach

The American Academy of Sleep Medicine recommends starting with behavioral interventions immediately upon admission, even in the acute hospital setting where full CBT-I may not be feasible 1, 3
Cognitive Behavioral Therapy for Insomnia (CBT-I) should be the initial treatment for all hospitalized patients with insomnia, with short-term pharmacotherapy reserved as an adjunct when behavioral interventions alone are insufficient or impractical in the acute inpatient setting 1, 2

Implement stimulus control: Patients should use the bed only for sleep, leave the bed if unable to sleep within approximately 20 minutes, and return only when drowsy 3
Maintain consistent sleep-wake schedules: Set regular bedtime and wake times despite the hospital environment disruptions 3
Optimize the hospital sleep environment: Minimize nighttime vital sign checks when medically safe, reduce noise and light exposure, avoid stimulating activities before bedtime, and limit caffeine intake after early afternoon 3

The American Academy of Sleep Medicine recommends zolpidem 10 mg (5 mg in elderly) as the preferred first-line agent for sleep onset insomnia, with proven efficacy for reducing sleep latency 2
Ramelteon 8 mg is an alternative first-line option, particularly for patients with substance abuse history or concerns about benzodiazepine receptor agonist risks 2
Suvorexant (orexin receptor antagonist) is recommended for sleep maintenance problems 1, 2

The American Academy of Sleep Medicine advises against using over-the-counter antihistamines (diphenhydramine) due to lack of efficacy data, anticholinergic side effects, daytime sedation, and delirium risk especially in elderly and medically ill patients 2, 6
Antipsychotics should not be used as first-line treatment due to problematic metabolic side effects and lack of evidence 2
Long-acting benzodiazepines (flurazepam) should be avoided due to extended half-life and increased fall risk 2, 5

Elderly patients require lower doses: Use zolpidem 5 mg maximum due to increased sensitivity, fall risk, and cognitive impairment 2
Limit pharmacotherapy to short-term use only (typically less than 4 weeks for acute insomnia), using the lowest effective dose for the shortest period possible 1, 2, 6

Patients with dementia or cognitive impairment should avoid benzodiazepines entirely due to unacceptable risk-benefit ratio with increased falls, cognitive impairment, dependence, and daytime sedation 4
Patients with cancer or advanced illness should have underlying causes of insomnia identified and treated first, and combine pharmacological and non-pharmacological approaches rather than relying on medication alone 6

The American Academy of Sleep Medicine recommends not prescribing hypnotics without implementing behavioral strategies, as combined approaches are more effective and allow for lower medication doses 4, 6
Do not continue pharmacotherapy long-term without periodic reassessment, as dependence and tolerance can develop 2
Do not use sedating agents without considering their specific effects: Match medication half-life to the patient's specific sleep complaint (onset vs. maintenance) 2, 5